MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In


News Categories




Alirocumab Reduces Cholesterol in Phase III Study

Treatment more effective than ezetimibe (October 16)

The phase III ODYSSEY MONO study of alirocumab (Sanofi/Regeneron), an investigational, fully human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), has met its primary efficacy endpoint.

The mean reduction in low-density lipoprotein cholesterol (LDL-C, or “bad” cholesterol) from baseline to week 24 — the trial’s primary efficacy endpoint — was significantly greater in patients treated with alirocumab compared with those treated with ezetimibe (Zetia, Merck) (47.2% vs. 15.6%, respectively; P < 0.0001). In the study, which included up-titration for patients who did not achieve an LDL-C level of 70 mg/dL, most of the patients continued to be treated with the initial low dose of alirocumab (75 mg).

Treatment-emergent adverse events (AEs) were reported in 69.2% of the alirocumab group and in 78.4% of the ezetimibe group. The most common type of AEs was infections (42.3% with alirocumab vs. 39.2% with ezetimibe), which included nasopharyngitis, influenza, and upper respiratory tract infections. Injection-site reactions occurred in fewer than 2% of patients in both groups. Muscle-related AEs occurred in 3.8% of patients treated with alirocumab and in 3.9% of patients treated with ezetimibe.

Alirocumab is administered via subcutaneous injection. By blocking PCSK9 — a determinant of circulating LDL-C levels in the blood — alirocumab increases the number of LDL receptors on hepatocytes, thereby lowering LDL-C levels.

Source: Regeneron; October 16, 2013.

More stories